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Chronic kidney disease (CKD) is a major global health concern, and the uremic state is
highly associated with fibrogenesis in several organs and tissues. Fibrosis is characterized
by excessive production and deposition of extracellular matrix proteins with a detrimental
impact on organ function. Another key feature of CKD is the retention and subsequent
accumulation of solutes that are normally cleared by the healthy kidney. Several of
these uremic retention solutes, including indoxyl sulfate and p-cresyl sulfate, have been
suggested to be CKD-specific triggers for the development and perpetuation of fibrosis.
The purpose of this brief review is to gather and discuss the current body of evidence
linking uremic retention solutes to the fibrotic response during CKD, with a special
emphasis on the pathophysiological mechanisms in the kidney.
Keywords: chronic kidney disease, renal fibrosis, cardiac fibrosis, uremic retention solutes, TGF-β , epithelial-to-
mesenchymal transition
Introduction
The kidneys are essential for the clearance of (metabolic) waste products. And even though
the primary cause of kidney disease (either acute or chronic) is often related to direct injury,
e.g., inflammatory damage in the case of glomerulonephritis and pyelonephritis, or hypoperfu-
sion, ischemia, and toxic damage, this will ultimately result in a reduced renal function. When
the kidneys fail to purify the body of metabolic end-products, a host of substances that are
normally excreted into the urine are retained. This condition is called uremia, after the first
recognized and most abundant retention product, urea. Many uremic retention solutes are bio-
logically active and exert toxicity, affecting the functional capacity of almost every organ system
in the body, resulting in the complex clinical picture of uremia (1). Currently, uremic reten-
tion products are most often classified according to their removal pattern by dialysis, which is,
up to now, the most frequently applied method to reduce solute levels in patients with end-
stage renal disease (ESRD). Three major groups are considered: (1) small water-soluble com-
pounds, molecular weight (MW) <500D, which are easy to remove by any type of dialysis; (2)
larger middle molecules, mostly peptides, MW >500D, which can only be cleared by dialyz-
ers containing large pore membranes (high flux dialysis); and (3) protein-bound compounds,
mostly with a low MW (<500D), these solutes are difficult to remove by any type of dialy-
sis, as protein binding hampers their clearance. Especially this class of retention solutes greatly
contributes to comorbidities, such as organ fibrosis, observed in chronic kidney disease (CKD)
patients.
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Fibrosis and Uremia: Clinical Aspects
Fibrosis is a process whereby functional tissue is replaced by
connective tissue. Once this phenomenon exceeds the level of
physiological repair, it will result in loss of organ architecture as
well as loss of functional tissue. Causes may be local damage, e.g.,
trauma, infection, or ischemia, but also more diffuse conditions,
like systemic inflammation. In what follows, we will summarize
the clinical consequences of fibrotic changes in uremia.
Renal Fibrosis
As stated above, kidney disease is often due to direct injury, yet
in many cases this initial insult will initiate fibrogenesis, espe-
cially when regeneration as healing process is inadequate (2). The
kidney is a complex organ containing a wide variety of cells that
constitute the glomeruli, tubules, interstitium, and capillaries (3).
And the initial site of injury determines the subsequent pathology,
e.g., glomerular IgA deposition will cause glomerular fibrosis,
whereas infections or proteinuria will provoke tubulointerstitial
fibrosis (3). Still, irrespective of etiology, the subsequent fibrotic
response will ultimately affect the functional capacities of the
kidney, with uremia as one of the consequences. To cope with
this problem, many strategies have been developed in hopes of
slowing down or even reversing fibrogenesis (4). Although several
studies have been successful at the pre-clinical level, only limited
advances have been made at this time in the translation of these
findings to the level of patient treatment (4). In addition, in
the analysis of the urinary proteome related to CKD and CKD
progression, a marked positive correlation appears with collagen
or matrix protein fragments, which via a bottom-to-top approach
confirms the pathophysiological role of fibrosis in the functional
disturbance of kidneys and other tissues in patients with CKD (5).
Cardiac Fibrosis
Similar to the kidney, fibrosis of the heart and its valves depends
on a host of damaging processes, such as ischemia or inflamma-
tion, with heart failure as the functional resultant. Many of the
factors that cause kidney failure, e.g., hypertension and diabetes,
concurrently promote cardiac fibrosis (6, 7), a condition induced
by uremic retention solutes as well (8, 9). In its turn, the ensuing
cardiac failure causes hypoperfusion and ischemia of the kidneys,
which is causative for uremia.
The Cardio-Renal Axis
All these elements together result in a close interaction of renal and
cardiac dysfunction, often termed, correctly or incorrectly, cardio-
renal syndrome (10, 11). Nevertheless, there is no debate that
kidney and heart dysfunction are closely intertwined, resulting in
a high cardiovascular burden in renal failure patients (12, 13).
Fibrosis of Other Organ Systems
It seems conceivable that uremia at large is a profibrotic condition,
whichmay be detrimental for organ systems other than the kidney
and heart. A study in CKD rats demonstrated the presence of
fibrosis in the peritoneal membrane, an organ system not directly
involved in hemodynamic homeostasis, within 6weeks (14).
The most clinically relevant organ system next to the heart and
the kidneys is the vascular bed. Vessel stiffness, a key pathophys-
iological feature of uremia, and at least in part the consequence
of fibrosis (15), results in systolic hypertension, diastolic hypop-
erfusion, a diminished physiologic response to orthostasis and
volume loss, and an enhanced risk of cardiovascular events such as
myocardial ischemia and ischemic and hemorrhagic stroke (16).
Thus, it is clear that organ fibrosis is a key feature of CKD,
yet the pathophysiological mechanisms underlying the fibrotic
response during uremia remain to be fully elucidated.
Uremic Solutes and Renal Fibrosis
Fibrosis is the end result of a complex cascade of cellular and
molecular responses initiated by organ damage (3). And even
though there is a range of organ-specific triggers, the fibrotic
process and associated signaling pathways are highly conserved
between different organs (3). Furthermore, in recent years,
epithelial-to-mesenchymal transition (EMT) has emerged as a
leading, yet highly debated, hypothesis for the origin of col-
lagenous matrix-producing myofibroblasts that contribute to the
fibrotic response (17–21). Renal fibrosis ends in uremia, yet ure-
mia per se will also further enhance the fibrotic process, because
of the direct biological effects of uremic toxins. In a recent sys-
tematic review on the toxicity of two uremic retention products,
e.g., indoxyl sulfate and p-cresyl sulfate, of the 27 retrieved high-
quality studies, at least five demonstrated a direct link to EMT
and/or kidney fibrosis (22). Therefore, the remainder of this
review will delineate the profibrotic impact of several uremic
solutes on the kidney (summarized in Table 1).
TGF-β Signaling Pathway in CKD
Transforming growth factor (TGF)-β is one of the key factors driv-
ing the fibrotic response in most organs. Binding of TGF-β to a
serine-threonine kinase type II receptor results in the recruitment
and phosphorylation of a type I receptor, which in turn phospho-
rylates SMADs thereby initiating a host of signaling cascades (3,
23). TGF-β is synthesized and secreted by inflammatory cells and
a variety of effector cells, and activation of the pathway results in
the formation and deposition of extracellular matrix proteins (3).
In 1992, the role of TGF-β in renal fibrosis was still uncertain (24),
yet in the following years more and more studies demonstrated
the involvement of this factor in renal fibrogenesis (25–27). More
recently, the interplay between uremic retention solutes, such as
indoxyl sulfate and p-cresyl sulfate, and TGF-β has gained more
scientific attention (28, 29).
Impact of Indoxyl Sulfate on Fibrogenesis
Indoxyl sulfate is a small organic aromatic polycyclic anion
derived from dietary tryptophan that has extensively been studied
in conjunction with CKD-associated cardiovascular disease (22),
and it is reported that this uremic solute can induce vascular calci-
fication and correlates with coronary artery disease and mortality
(30–32). Indoxyl sulfate is thought, however, to also contribute to
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TABLE 1 | Profibrotic effects of uremic solutes.
Solute Chemical
formula
Avg.
MW
TGF-β PAI-1 COL1A1 Interstitial
fibrosis
Glomerular
sclerosis
EMT Senescence Klotho Model(s) Reference
Indoxyl
sulfate
C8H7NO4S 213.2 " " " p p # In vitro/
In vivo
(28, 33, 34,
38, 39,
42–44, 46,
47, 53, 54)
p-Cresyl
sulfate
C7H8O4S 188.2 " " p # In vitro/
In vivo
(39, 54, 57)
p-Cresyl
glucuronide
C13H16O7 284.3
p In vitro (56)
Hippuric acid C9H9NO3 179.2
p In vivo (60)
Indole-3-
acetic
acid
C10H9NO2 175.2 " p p In vitro/
In vivo
(28, 60)
Leptin Protein " " In vitro/
In vivo
(66–68)
Marino-
bufagenin
C24H32O5 400.5 " p p In vitro/
In vivo
(76)
" increased expression; # decrease expression; p induced.
Avg. MW, average molecular weight; COL1A1, alpha-1 type I collagen; EMT, epithelial-to-mesenchymal transition; PAI-1, plasminogen activator inhibitor-1; TGF-β, transforming growth
factor-β.
a plethora of pathologies observed in dialysis patients, including
tubulointerstitial inflammation and whole-kidney damage (22).
Already in the 1990s, studies were published linking indoxyl
sulfate to progression of renal disease as well as renal fibrosis
(33, 34). Miyazaki et al. observed that indoxyl sulfate overload
augmented the gene expression of tissue inhibitor of metallo-
proteinases (TIMP)-1, intercellular adhesion molecule (ICAM)-
1, alpha-1 type I collagen (COL1A1), and TGF-β in the renal
cortex of 5/6-nephrectomized rats (33, 34). Moreover, indoxyl
sulfate stimulated the production of TGF-β by renal proximal
tubular cells in vitro (34). Almost a decade later, it was demon-
strated that exposure of HK-2 cells to indoxyl sulfate resulted in
a reactive oxygen species (ROS)-mediated up-regulation of plas-
minogen activator inhibitor (PAI)-1 (28), a downstream signaling
molecule of the TGF-β pathway associated with most aggressive
kidney diseases (35–37). Furthermore, Saito et al. reported that
indoxyl sulfate can increase α-smoothmuscle actin (α-SMA) and
TGF-β expression in HK-2 cells by activation of the (pro)renin
receptor through ROS-Stat3-NF-κB signaling (38). Also inmouse
renal proximal tubular cells, it was demonstrated that indoxyl
sulfate activates the TGF-β pathway, as illustrated by an increased
SMAD2/3 phosphorylation (39).
Although the contribution of EMT to fibrosis remains contro-
versial, phenotypic alterations reminiscent of EMT, also referred
to as epithelial phenotypic changes (EPC), might play a role in the
fibrotic response as well as disease progression (40, 41). Several
studies have demonstrated that indoxyl sulfate induces EMT, as
demonstrated by a reduced expression of E-cadherin and zona
occludens (ZO)-1, and increased expression of α-SMA in rat
kidney as well as rat proximal tubular (NRK-52E) cells (42, 43).
Furthermore, Sun et al. reported that treatment with indoxyl sul-
fate increased the expression of the EMT-associated transcription
factor Snail, concurrent with an elevated expression of fibronectin
and α-SMA as well as a diminished expression of E-cadherin
in both mouse kidneys and murine proximal tubular cells (39).
Similar effects of indoxyl sulfate have also been observed in human
renal cell models (42, 44).
Renal cells can become senescent due to a variety of (stress)
triggers, including aging, and these cells, while in growth arrest,
can contribute to renal fibrosis by secreting profibrotic cytokines
and growth factors (45). It has been demonstrated that exposure
of HK-2 cells to indoxyl sulfate resulted in an increased expression
of p53 and p65, and augmented β-galactosidase activity (46, 47),
indicating that indoxyl sulfate induces senescence.
Lastly, the renoprotective anti-aging factor klotho, which is
involved in amyriad of homeostatic processes (48–50),mightmit-
igate renal fibrosis by suppressing TGF-β signaling and vice versa,
deficient klotho expressionmay accelerate senescence and fibrosis
(51, 52). Adijiang et al. reported that in both Dahl salt-resistant
normotensive and Dahl salt-sensitive hypertensive rats, treatment
with indoxyl sulfate resulted in lower gene expression of klotho
(53). These findings were corroborated by the study of Sun and
colleagues showing that indoxyl sulfate suppressed klotho expres-
sion in murine renal proximal tubules as well as HK-2 cells (54).
Taken together, it is evident that indoxyl sulfate can contribute
to renal fibrogenesis via an array of pathophysiological mecha-
nisms (Figure 1), e.g., ROS production, stimulating expression of
the profibrotic factor TGF-β, induction of EMT/EPC, promoting
cellular senescence and by reducing klotho expression.
Profibrotic Activity of Other Protein-Bound
Solutes
Next to indoxyl sulfate, several other uremic solutes have been
linked to renal fibrosis, most prominently the p-cresol metabolite,
p-cresyl sulfate (22, 29). p-Cresol is formed by colonic bacteria
from dietary tyrosine and this parent compound is either con-
jugated to sulfate or glucuronic acid giving rise to circulating
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FIGURE 1 | The profibrotic effects of indoxyl sulfate. Schematic
presentation of the pathophysiological mechanisms via which indoxyl sulfate
promotes fibrogenesis in renal cells. Furthermore, similar effects have been
described for other protein-bound uremic retention solutes, e.g., p-cresyl
sulfate. See text for details. Chemical structure obtained from the Human
Metabolome Database (www.hmdb.ca). α-SMA, α-smooth muscle actin;
EMT, epithelial-to-mesenchymal transition; PAI-1, plasminogen activator
inhibitor-1; COL1A1, alpha-1 type I collagen; ROS, reactive oxygen species;
TGF-β, Transforming growth factor-β; TIMP-1, tissue inhibitor of
metalloproteinases-1.
p-cresyl sulfate or p-cresyl glucuronide (55). Themain profibrotic
effect currently described for p-cresyl sulfate is the induction of
TGF-β (protein) expression. Sun et al. reported that exposure of
murine renal proximal tubular cells to p-cresyl sulfate resulted in
an increased expression of TGF-β and SMAD phosphorylation,
concurrent with the induction of EMT (39). Conversely, in human
conditionally immortalized renal proximal tubule epithelial cells,
p-cresyl sulfate failed to induce EMT, whereas p-cresyl glu-
curonide did promote phenotypical changes associated with EMT
(56). Furthermore, Watanabe et al. showed a ROS-dependent
production and secretion of TGF-β protein in HK-2 cells upon
treatment with p-cresyl sulfate (57). Moreover, they reported that
p-cresyl sulfate increased the gene expression of TIMP-1 and
COL1A1 (57). And, similar to indoxyl sulfate, it has been demon-
strated that p-cresyl sulfate mitigated the expression of klotho in
both murine and human renal cell models (54).
Two other widely studied uremic solutes are hippuric acid and
indole-3-acetic acid. Both protein-bound compounds have delete-
rious effects on normal renal (metabolic) functioning (58, 59), yet
there is scant evidence for their potential impact on fibrosis. Satoh
and colleagues demonstrated that treatment with either hippuric
acid or indole-3-acetic acid induced glomerular sclerosis in rats
(60). And indole-3-acetic acid stimulated interstitial fibrosis (60).
Also, it has been reported that indole-3-acetic acid activated the
TGF-β pathway in HK-2 cells, as illustrated by an increased
expression of PAI-1 (28).
Thus, several of the protein-bound uremic retention solutes,
although chemically very diverse entities, can elicit similar toxic
effects thereby promoting renal fibrosis. Yet, the majority, if not
all, of this evidence has been obtained experimentally in animals
or by in vitro studies, whereas clinical studies on this aspect are
virtually absent. Therefore, far more (clinical) research is needed
to fully characterize the possible profibrotic effects of the more
than 150 cataloged uremic retention solutes.
New Kids on the Block
Next to the widely studied protein-bound uremic toxins, several
other lesser-known retention solutes might play a role in renal
fibrosis, for instance leptin and marinobufagenin (MBG).
Leptin (from the Greek word leptos, meaning “thin”) is a prod-
uct of the obese gene, identified in 1994 (61), and is secreted by
adipocytes. Activation of its signaling pathway in the hypothala-
mus reduces food intake and increases energy expenditure. This
adipocytokine is eliminated from the circulation via the kidneys
mainly by metabolic degradation in the tubules (62). And it has
been reported that serum leptin levels are increased in CKD
and ESRD patients (63, 64). The mechanisms underlying leptin
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retention are complex as reviewed by Alix et al.: decreased renal
clearance, increased fat mass, hyperinsulinemia, and low-grade
chronic inflammation all contribute to hyperleptinemia in CKD
patients (65). Furthermore, it has been reported by Wolf and
colleagues that leptin plays a role in the progression of renal fibro-
genesis (66). They demonstrated that leptin triggers glomerular
endothelial cell proliferation via TGF-β. In addition, Briffa et al.
reported that leptin increased TGF-β production and secretion
in opossum kidney proximal tubule cells (67). Furthermore, it
is shown that leptin stimulates COL1A1 production in renal
interstitial (NRK-49F) fibroblasts (68). Moreover, hyperleptine-
mia is associated with increased blood pressure, a known risk
factor for renal fibrosis, and additional deleterious (potential
profibrotic) effects of this adipocytokine have been described in
experimental and clinical studies (69, 70). Noteworthy, two classes
of compoundswith similar damaging effects on the cardiovascular
system as leptin are dimethylarginines and advanced glycation
end-products; however, more studies are needed to unveil the sus-
pected profibrotic potential of these compounds. For an overview
of the toxicity of both groups of solutes, the interested reader is
referred to the reviews by Schepers et al., and Mallipattu et al.
(71, 72).
Marinobufagenin belongs to the family of endogenous car-
diotonic steroids (CTS), also known as digitalis-like factors, and
is produced by adrenal cortical cells (73). MBG is a Na+ /K+ -
ATPase inhibitor that specifically binds to the α subunit of the
sodium pump. This results in renal sodium excretion, increased
myocardial contractility, and vasoconstriction (73). Therefore,
CTS derived from dried toad skins were already used 1000 years
ago in traditional medicine to treat congestive heart failure. Ele-
vated levels of MGB have been detected in CKD and hemodialysis
patients (74, 75), and Fedorova et al. reported that MBG stim-
ulated renal fibrosis in rats as well as increased tubular expres-
sion of Snail (76). Furthermore, they demonstrated that MGB
induced EMT in LLC-PK1 cells as observed by increased lev-
els of collagen I, fibronectin, and vimentin (76). In line with
the observed profibrotic effect of MBG, it was reported that
immunization against this steroid attenuated renal fibrosis in
5/6-nephrectomized rats (77).
These thought-provoking results warrant further scrutiny and
without a doubt many more uremic retention solutes may be
classified as profibrotic in the near future.
Future Directions
CKD is a growing health concern and renal fibrosis is an inte-
gral part of the pathophysiological mechanism underlying disease
progression. Current therapies for renal fibrosis mainly focus on
the etiology of the disease, such as hypertension or diabetes,
and as such show only limited efficacy in halting the fibrotic
process (3). A key feature of uremia is the accumulation of a wide
array of potential toxic solutes and slowly a body of evidence is
emerging implicating these retention solutes as culprits in CKD-
associated (renal) fibrogenesis. Therefore, therapies aimed at lim-
iting the intake/absorption/production of uremic solutes, such as
oral adsorbents or probiotics (78–80), or treatment modalities
supporting the clearance of these compounds, e.g., living dialysis
membranes (81), will most likely have a great potential for slowing
fibrosis. Moreover, better understanding of the profibrotic effects
of the multiplicity of uremic retention solutes will further aid in
unveiling novel therapeutic targets.
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